1. In vitro evaluation of meropenem-vaborbactam against clinical CRE isolates at a tertiary care center with low KPC-mediated carbapenem resistance.
- Author
-
Kinn PM, Chen DJ, Gihring TM, Schulz LT, Fox BC, McCreary EK, and Lepak AJ
- Subjects
- Bacterial Proteins metabolism, Carbapenem-Resistant Enterobacteriaceae enzymology, Carbapenem-Resistant Enterobacteriaceae isolation & purification, Drug Combinations, Enterobacteriaceae Infections epidemiology, Humans, Microbial Sensitivity Tests, Tertiary Care Centers, Wisconsin epidemiology, beta-Lactamases metabolism, Anti-Bacterial Agents pharmacology, Boronic Acids pharmacology, Carbapenem-Resistant Enterobacteriaceae drug effects, Drug Resistance, Bacterial drug effects, Enterobacteriaceae Infections microbiology, Meropenem pharmacology, beta-Lactamase Inhibitors pharmacology
- Abstract
The in vitro activity of meropenem-vaborbactam was examined against clinical carbapenem-resistant Enterobacteriaceae isolates collected over 3 years at our medical center. Only 3 KPC-producers were identified. Susceptibility to meropenem-vaborbactam was noted in 15/16 (94%) isolates (MIC
90 2 mg/L) that were nonsusceptible to meropenem. Meropenem-vaborbactam may have utility at centers where non-KPC-producers are more frequent., (Copyright © 2018 Elsevier Inc. All rights reserved.)- Published
- 2019
- Full Text
- View/download PDF